Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial
贝伐珠单抗、替雷利珠单抗和白蛋白紫杉醇联合治疗既往未接受治疗的转移性三阴性乳腺癌:一项 II 期试验
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2024-011314
Chen, Meiting; Huang, Riqing; Rong, Qixiang; Yang, Wei; Shen, Xiujiao; Sun, Qi; Shu, Ditian; Jiang, Kuikui; Xue, Cong; Peng, Jing; An, Xin; Li, Haifeng; Xu, Fei; Shi, Yanxia